Business
Codexis uses its CodeEvolver technology to discover, improve, and commercialize enzymes for therapeutics manufacturing, including ECO Synthesis and small-molecule pharma biocatalysis.
Codexis grew revenue and narrowed losses, but still burned FCF, carried more debt, and had insider sales alongside one buyer.
The read at a glance✓ Audited against SEC data
- Business mix — Enzyme technologyNote
- Revenue — $70.4M, +18.6%OK
- Net loss — ($44.0M), narrowerWatch
- FCF — ($23.8M)Watch
- Debt — $40.1M, +38.7%Watch
- Insiders — 5 purchases and 16 salesNote
- Accounting — Altman weak; Beneish N/A; EQ greyWatch
Where the revenue comes from
Fiscal 2025, as CODEXIS, INC. reports it. History and quarterly detail are in the app.
- Research and development revenue$44.4M
- Product revenue$26.0M
Leadership changes
From CODEXIS, INC.'s own filings, the day they're filed.
- Dennis Wolf · Directors · departureeff. 2026-04-08
- Georgia Erbez · Chief Financial Officer · appointmenteff. 2024-09-30
- Alison Moore · directors · departureeff. 2024-09-30
Latest filings
- 10-Q · Quarterly report2026-08-11
- 8-K · Company announcement2026-08-11
- 8-K · Company announcement2026-07-27
- 8-K · Company announcement2026-07-23
- 8-K · Company announcement2026-06-22
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about CODEXIS, INC., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.